Computational Biology Training in Hematology Hall of Fame

Translational Research Training in Hematology Hall of Fame

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Biology of Hodgkin lymphoma in older patients project

An SWG Grant-supported project initiated by the EHA SWG on Ageing in Hematology.

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

“Nothing about us without us”: how patient advocacy is changing the game

Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.